Mark Arnold Hagler - 24 Apr 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: President and Chief Commercial Officer
Issuer ticker: NBP
Reported as of: 24 Apr 2026
Net transaction value: +$577,300
SEC form: 4
Accepted by SEC: 28 Apr 2026, 16:05:04 UTC
Prior SEC filing: 22 Apr 2026
Next SEC filing: 10 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact

Key filing fact

Mark Arnold Hagler filed Form 4 for NovaBridge Biosciences (NBP) on 28 Apr 2026.

Key facts

This page summarizes Mark Arnold Hagler's Form 4 filing for NovaBridge Biosciences (NBP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 22 Apr 2026.
Current net transaction value: +$577,300.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002126029 Primary reporting owner

Hagler Mark Arnold

Relationship: President and Chief Commercial Officer
Address: C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Purchase

Transaction value: $577,300
Shares: +230,000
Change %
Price: $2.51
Shares after: 230,000
Date: 24 Apr 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

The reported securities are represented by 100,000 ADSs.

Footnote F3

The price reported in Column 4 is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $2.44 to $2.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC remarks

President and Chief Commercial Officer